Cancer and New Drugs · global
Opening the Door to Immunotherapy for Hard-to-Treat Colorectal Cancer: ADG126 Combination Enters Phase 1 Trial
City of Hope will test a masked CTLA-4 antibody in combination with a PD-1/VEGF bispecific antibody, first identifying a safe dose before exploring the addition of chemotherapy. No efficacy results have been announced for this study, and whether it can overcome treatment challenges in microsatellite-stable tumors remains a question for human data.
Immunotherapy has changed treatment options for some patients with colorectal cancer, but those gains have been difficult to extend directly to microsatellite-stable (MSS) tumors. Finding ways to enable the immune system to attack cancer cells effectively remains a major drug development challenge for these patients. On November 17, City of Hope in the United States and Adagene announced the launch of a Phase 1 clinical trial, seeking a breakthrough through a strategy that combines immune modulation with inhibition of angiogenesis.
According to their announcement, the study plans to enroll up to 36 patients with advanced MSS colorectal cancer and will be led by City of Hope oncologist Marwan G. Fakih. The team will first evaluate the combination of ivonescimab and muzastotug (ADG126) in patients whose disease has progressed despite prior systemic therapy, seeking a dose that balances safety with preliminary antitumor activity.
The two antibodies target different processes. Ivonescimab targets both the immune checkpoint PD-1 and VEGF, which promotes angiogenesis, seeking to relieve immune suppression and interfere with tumor blood vessel formation; ADG126 targets another immune checkpoint, CTLA-4. The study's central hypothesis is that these effects can work together within tumors, but any synergistic effect must still be validated in the new trial.
ADG126 also incorporates a “masking” design. According to Adagene, the antibody is expected to be activated more readily in the tumor microenvironment, thereby reducing its activity in healthy tissues. This design aims to improve the treatment's therapeutic window; whether that advantage can be maintained when combined with ivonescimab remains a question that human studies must answer.
If a suitable dose can be established, the team plans to add fluorouracil (5-FU), then explore adding irinotecan and assess the possibility of moving into earlier lines of treatment. The maintenance and first-line treatment uses mentioned in the announcement therefore remain development directions, rather than clinical options with demonstrated efficacy.
The significance of this study lies in bringing a combination with complementary mechanisms into early human evaluation. The announcement provided no results on patient responses, survival, or adverse events for the new combination, and it cannot establish that the combination is superior to current treatments. The news comes primarily from the announcement by the research institution and the drug developer; the announcement also disclosed that study leader Fakih serves as a paid consultant to Adagene. Whether the team can identify a tolerable dose and observe efficacy signals sufficient to support subsequent trials will determine how far this approach can progress.